SUMMARY A lack in prostacyclin (PGI2) production due to atherosclerosis may play a role in the pathophysiology of some of the clinical manifestations of ischemic heart disease and, in particular, of coronary vasospasm. We therefore evaluated the effects of i.v. PGI, in nine patients with variant angina and six normal volunteers.
volunteers.
In normal subjects, PGI2 (2.5, 5, 10 and 20 jg/kg/min) had significant antiplatelet effects, caused a dosedependent decrease in both systolic and diastolic arterial pressure and a decrease in pulmonary resistance. Heart rate increased in a dose-dependent manner, but no consistent effects on myocardial contractility (evaluated by ultrasound) were observed. Side effects were negligible and readily reversible.
Although producing obvious antiplatelet and vasodilatory effects, PGI2 did not affect the number, severity and duration of spontaneous ischemic episodes due to coronary vasospasm in five patients and ergonovineinduced spasm in three. However, the number of ischemic episodes was consistently reduced in one patient during four consecutive periods of PGI2 infusion alternated with placebo. A severe, prolonged ischemic episode with ST elevation and pain was consistently observed in this patient every time PGI2 was discontinued.
In the appropriate environment, PGI2 can be administered safely to patients with ischemic heart disease. Occasionally, PGI2 may result in a complete disappearance of ischemic episodes due to coronary vasospasm, but usually it is ineffective. These conflicting results could be related to different etiologies of coronary spasm. PROSTACYCLIN (PGI2), an arachidonic acid metabolite produced by the vascular endothelial cells and by the lungs,'-3 exerts powerful vasodilating and antiplatelet effects in vitro4-8 and in vivo.9-' These effects may avoid intravascular thrombosis, maintain endothelial integrity and, possibly, control vascular smooth muscle tone. Decreased PGI2 production by the atherosclerotic arterial wall might play a role in some of the clinical manifestations of ischemic heart disease.'3 20 Maseri et al. 2' suggested that coronary vasospasm could result from an increased vascular sensitivity to vasoconstrictor stimuli, secondary to a reduction in local PGI2 production at the site of atherosclerotic lesions. Moreover, the hypothesis that transient coronary vasospasm might be precipitated by thromboxane A2, locally released by aggregating platelets,22 in the presence of endothelial lesions has recently gained attention. 21 23-25 Finally, cyclical transient reduction in coronary flow, occurring in experimentally narrowed coronary arteries,26-28 has been prevented by the administration of PGI2. 28 In a preliminary study, we investigated the hemodynamic, antiplatelet and possible side effects of PGI2 in six healthy volunteers. In a second study, we eva uated the effects of PGI2 infusion in nine patients with variant angina, traditionally considered a clinical landmark of transient coronary vasospasm.29 8 
Material and Methods

Study I
Subjects
Five healthy male subjects, all coauthors of the present report (SC, GC, GAC, AM and CP), ages from 32-50 years (mean age 38 years) volunteered for the study. One male patient (NV), age 34 years, submitted to routine coronary angiography and coronary sinus catheterization because of atypical precordial pain. He gave informed consent to the infusion of the drug after the completion of the diagnostic study, which had failed to demonstrate coronary lesions or hemodynamic or myocardial metabolic abnormality. cubital vein at rates of 2.5, 5, 10 and 20 ng/kg/min (0.025, 0.05, 0.1 and 0.2 ml/min, respectively), for consecutive periods of 30 minutes each. During the infusion, the PGI2 temperature was kept constant at 2°C. The biologic activity of PGI2, assessed by its effects on ADP-induced platelet aggregation was checked before and at the end of each experiment by incubating 0.01 ml of the solution (containing 10 ng of PGI2) with I ml of platelet-rich plasma.
Protocol
In four subjects, a 16G polyethylene catheter was positioned in the mid-right atrium under fluoroscopic control. In AM and NV, pulmonary arterial (PAP) and right atrial pressures (RAP) were continuously monitored through a Swan-Ganz thermodilution catheter (Edwards Laboratories). In NV, continuous measurements of left ventricular (LV) pressure and dP/dt were obtained by a pigtail catheter. The catheters were connected to Statham P23Db pressure transducers adjusted to equal sensitivity and continuously perfused with normal saline. The pressure signals and one ECG lead were continuously recorded on analog magnetic tape and played back on photographic paper for subsequent analysis. Arterial pressure was measured by a cuff manometer every 3-5 minutes. In AM and NV, the cardiac output (CO) was measured by the thermodilution technique.35 In each instance, at least five consecutive CO measurements were obtained by an Edwards 9520 instrument; CO was calculated as the mean of the last three consistent measurements. Transcutaneous aortic flow velocity (TAV) was measured in five subjects by a Doppler technique, according to the method of Light and Cross.36' 37 The measurements derived from the TAV recordings were the time-averaged (mean) flow velocity and the area of each TAV complex, which have been shown to reflect directional changes in CO and stroke volume (SV), respectively.37 8 Standard M-mode echocardiographic tracings were obtained using an Echo-Cardio-Visor 03 instrument (Organon Teknika) to calculate LV and atrial dimensions and LV percent fractional shortening. Citrated blood samples were obtained under basal conditions, at the end of the 2.5-and 20-ng infusions and 60 minutes after the end of the infusion. In vitro aggregation of platelet-rich plasma was assessed in a standard Born aggregometer using incremental doses of ADP. In three subjects, hemodynamic and platelet aggregability were also measured during a 30-minute infusion of the vehicle alone (TRIS buffer) at the highest rate (0.2 ml/min).
Study 2 Patients
We studied nine patients (eight males and one female), ages [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] Coronary arteriography, performed in seven patients by the Judkins technique, revealed three-vessel disease in three patients, two-vessel disease in two and one-vessel disease in two. A transient episode of coronary vasospasm accompanied by ECG changes similar to those recorded in the coronary care unit (CCU) was documented in five (spontaneous in two, induced by ergonovine maleate in three). Patients PE and FF did not give consent to coronary arteriography.
Before the study, all patients underwent continuous ECG monitoring in the CCU for at least 3 days to assess objectively the frequency and the temporal distribution of the ischemic episodes, with or without anginal pain.
The ECG lead showing the most evident ST-T changes during the episodes was selected for this purpose. Six patients showed more than 10 episodes per day and were selected for the continuous infusion of PGI2. The other three patients had a low daily frequency of ischemic episodes and a positive response to ergonovine, and we studied the effects of PGI2 on ergonovine-induced coronary vasospasm in these patients. The clinical, ECG and angiographic data are listed in table 1.
Protocol
PGI2 was prepared as described for study 1 and infused intravenously with a constant-flow Harvard pump through a polyethylene catheter introduced percutaneously and advanced in the superior vena cava. The biologic activity of the drug was checked, as described for study 1, at the beginning and at the end of each infusion period.
In each patient, the rate of infusion was increased progressively by 4 ng/kg/min every 5 minutes (with a maximum of 20 ng). The maximal dose tolerated without unpleasant side effects was then continued. Doses ranged from 8-20 ng/kg/min.
PGI2 Infusion in Spontaneous Angina
In each patient, the drug was administered during the time of day when the greatest number of episodes had been documented during continuous ECG monitoring. PGI2 or the vehicle alone were alternately infused for four consecutive periods of 3 hours each. In patient PE, the infusion was repeated on 2 successive days. The ECG lead showing the most obvious changes during the ischemic episodes was continuously monitored on the CCU central station and simultaneously analyzed in real time by a computer program with beat-by-beat display of heart rate and ST-T positive and negative areas.39""' The data were also simultaneously recorded on an analog magnetic tape. Arterial pressure (cuff) was measured every 5 minutes in the first 30 minutes of each infusion period and then every 30 minutes. Citrated blood samples In the three patients in whom a transient ischemic episode with ST-segment elevation could be induced by i.v. injection of ergonovine maleate (doses of 0.025-0.2 mg, administered in scalar doses), the test was repeated 30 minutes after a PGI2 infusion had been started according to the protocol for infusion during spontaneous angina. The ECG was continuously monitored; arterial pressure measurements (cuff) and a 12-lead ECG tracing were obtained every minute.
Results
The biologic activity of PGI2 did not change significantly between the beginning and the end of each infusion period. The percent inhibition of ADPinduced in vitro platelet aggregation at the beginning and at the end of the infusions was 87 ± 9% and 82 + 5%, respectively.
In all subjects and patients, PGI2 infusion produced skin flushing, especially marked on the face and the palms, accompanied by a sensation of warmth in the same areas. Two subjects complained of headache and three of restlessness. Three patients experienced nausea and one vomited. Side effects disappeared a few minutes after the infusion was stopped or the rate was reduced.
Study I Hemodynamic Effects
The hemodynamic findings during control and PGI2 are summarized in table 2. PGI2 infusion resulted in a significant dose-dependent drop in both systolic (10 ± 3%, mean ± SD) and diastolic (19 ± 5%) arterial pressure (p < 0.05 and 0.01, respectively) at doses of 20 and 10 ng/kg/min. Heart rate increased progressively during the infusion and reached a maximum during the 20-ng stage (21 ± 5%,p < 0.01). No consistent changes in right atrial pressure occurred at any of the infusion rates. All subjects showed a progressive increase in transcutaneous mean aortic flow velocity, with a maximum (47 ± 27%, p < 0.01) at the end of the 20-ng infusion stage without significant changes in the TAV index of SV. None of the echocardiographic variables measured changed significantly during the infusion. In subject AM, both systolic and diastolic PAP decreased (20% and 35%, respectively) but remained unchanged in NV.
CO increased progressively in both subjects AM and NV, reaching a maximum (average of 32%) at the end of the 20-ng infusion stage, but SV was practically unchanged. LV end-diastolic pressure decreased 3 mm Hg in NV, without any appreciable changes in LV Abbreviations: HR = heart rate; SAP = systolic arterial pressure; DAP = diastolic arterial pressure; MAP = mean arterial pressure; EDD = end-diastolic diameter (echo); ESD = end-systolic diameter (echo); FS% = percent fractional shortening; TAV-M = transaortic flow mean velocity; TAV-SV = transaortic flow velocity index of stroke volume; C = control; R = recovery. dP/dt max or min. All hemodynamic measurements returned to the control levels within 15 minutes after the end of the infusion.
Effects of Platelet Aggregability
ADP-induced platelet aggregation was reduced in all subjects at the dose of 20 ng/kg/min (64 ± 8%). In GC, an antiaggregatory effect (47%) was already evident at the dose of 2.5 ng/kg/min. The platelet aggregability returned to the control level within 1 hour after the end of the infusion in subjects SC, CP, and AM, but it was still 32 ± 5% lower than control in GC, GAC and NV. No changes in hemodynamics or in vitro platelet aggregation were observed in three subjects in whom the vehicle alone was infused, at the highest rate, for 30 minutes.
Study 2 Effects on Platelet Aggregation and Hemodynamics
The results of ADP-induced platelet aggregation during control and PGI2 infusion in the individual patients are summarized in figure 1. PGI2 reduced both primary and secondary platelet aggregation induced by ADP (54 ± 35% and 46 ± 24%, respectively). Mean arterial pressure decreased from 107 ± 12 to 93 ± 12 mm Hg (p < 0.01) and heart rate increased from 72 ± 8 to 87 ± 10 beats/min in the first 30 minutes of PGI2 infusion (p < 0.05). Arterial pressure returned to the control levels within 1 hour after the onset of the infusion in three patients and remained slightly reduced in the other three. Heart rate remained elevated in all patients throughout the infusion. During PGI2 administration, three patients showed marked bradycardia accompanied by severe hypotension, nausea and diffuse diaphoresis, which promptly disappeared when the infusion rate was reduced.
Effects on Spontaneous Ischemic Episodes
During the study we recorded 90 ischemic episodes, 54 of which were characterized by ST-segment elevation and 36 by pseudonormalization or peaking of T wave. Only 21 were accompanied by angina.
PGI2 did not affect the number, severity and duration of episodes of acute myocardial ischemia in five patients; the total number of ischemic episodes during the two placebo and PGI2 periods were 17, 16, 33 and 24 respectively; the differences were not statistically significant ( fig. 2) . Accordingly, no significant difference was found between the number of ischemic episodes recorded during the two PGI2 infusion periods and the corresponding periods of the days before and after the study ( fig. 3) . However, patient PE appeared to respond consistently to PGI2 infusion. The number of ischemic episodes was reduced from six during placebo to two during PGI2 when the drug was infused at a rate of 10 ng/kg/min, and no ischemic episodes were observed during three periods of PGI2 given at a rate of 20 ng/kg/min, while in the three corresponding placebo periods, four, three and five ischemic episodes were observed. Furthermore, a prolonged and severe episode accompanied by pain consistently occurred every time PGI2 infusion was stopped (fig. 4) .
Effects on Ergonovine-induced Coronary Vasospasm
Under control conditions, ergonovine maleate produced a complete focal spasm of the left anterior descending coronary artery in two patients and severe diffuse caliber reduction with delay in filling of the circumflex in one. The spasm was superimposed on a critical lesion in two patients and occurred in an angiographically normal vessel in one. It was accompanied by ST-segment elevation in the anterior leads in the first two patients and ST-segment depression in the anterolateral precordial leads in the third one. No apparent differences in severity and duration of ECG ischemic changes were noted in two patients when the same dose of ergonovine maleate was given during PGI2 infusion. The patient who showed ST-segment depression and incomplete spasm during the control test had ST-segment elevation in the same leads during PGI2.
Discussion
Continuous infusion of PGI2 in normal subjects produced antiplatelet effects similar to those described previously42-44 and a dose-dependent drop in arterial pressure, accompanied by an increase in heart rate and CO. PAP also fell during PGI2 in one subject and remained unchanged in the other. Therefore, in man, as in several other animal species,9'13 PGI2 decreases both systemic and pulmonary resistance. Since no changes in RA pressure or in left atrial and LV dimensions suggestive of venous pooling became evident during the infusion, the drug seems to affect primarily arterioles rather than capacitance vessels, in accordance with previous findings. 44 The increase in heart rate during the infusion may be consequent to a baroreceptor reflex or produced by a direct effect of the drug on sinus node automaticity. 45 The absence of significant effects on SV, echocardiographic indexes of myocardial contractility and LV dP/dt rules out a primary inotropic effect of the drug. The marked increase of the TAV index of SV in subject CP, who showed the largest drop in systolic and diastolic arterial pressure, was probably due to reduced ventricular afterload.
Therefore, PGI2 in man produces obvious vasodilatory and antiplatelet effects and may be useful in the management of patients with acute ischemic syndromes, especially if ischemia is produced by coronary vasospasm.
A localized decrease in arterial PGI2 could facilitate However, patient PE consistently showed a dramatic reduction in the number of ischemic episodes. The attacks were significantly reduced when PGI2 was infused at a rate of 10 ng/kg/min and completely abolished during three consecutive infusions of 20 ng/kg/min, suggesting a dose-dependent effect of the drug. The prolonged ischemic episodes consistently observed' after each PGI2 infusion suggests a rebound in coronary vasoconstriction due to the acute withdrawal of the drug. We could not find any clinical feature to account for his different response to the drug, except for a low platelet count (60,000/ml) consequent to hepatic cirrhosis and hypersplenism. The favorable response to PGI2 in this patient could also be related to the fact that his variant angina was not caused by vasospasm. However, the positive response to ergonovine makes this hypothesis unlikely.
Several factors may account for the conflicting results. Coronary vasospasm is likely to result from different stimuli affecting the vascular tone;21 their relative role in the individual patient will condition the therapeutic effect of a specific agent. However, no information is available on the actual physiologic levels of circulating PGI2, 'its role in the regulation of coronary tone, or the relative importance of circulating and local vascular PGI2. Furthermore, the action of exogenous PGI2 on the human coronary circulation is not clear. In vitro incubation of PGI2 with isolated human coronaries produces a paradoxic increase in vascular tone when high concentrations are used." Finally, the fate of exogeneous i.v. PGI2 is unknown. Prolonged incubation of PGI2 with human plasma leads to the formation of a new unidentified compound which, although retaining the antiplatelet effects, contracts instead of relaxes isolated bovine coronary strips. 47 Szczeklik et al. 48 described the results of a longterm (72-hour) i.v. infusion of PGI2 in seven patients with angina at rest who apparently did not'respond to conventional treatment with oral nitrates. Symptoms com'pletely disappeared in five patients and improved in two. 48 The authors suggested that PGI2 prevented ischemic episodes by avoiding the formation of platelet microaggregates releasing the vasoconstrictor thromboxane A2 in the coronary circulation. However, in a recent study in patients with variant angina, we could not find significant difference in the number of ischemic episodes recorded during control and after complete blockade of platelet thromboxane A2 with low-dose aspirin. 49 The significa'nce of the finding reported by Szczeklik et al. is difficult to assess because no information is provided on the number of attacks in the run-in period or on the associated antianginal treatment; the occurrence of transient acute myocardial ischemia was not evaluated objectively, and the effects of PGI2 were not compared with those of placebo.
In conclusion, our study demonstrates that in man, PGI2 has antiplatelet and vasodilatory effects similar to those observed in several other animal species. Its use appears safe in the appropriate environment in patients with ischemic heart disease. The side'effects promptly disappear when the infusion rate of the drug is reduced. Occasionally, the acute administration of PGI2 may result in the complete disappearance of episodes of acute myocardial ischemia due to coronary vasospasm, suggesting that a generalized or local reduction in PGI2 production could contribute, cholesterol. High levels of LDL cholesterol are related to increased risk of CHD and high levels of HDL cholesterol may protect against CHD.'8 17 There has been increased interest in HDL cholesterol because its negative relationship with CHD is stronger than the positive relationship between CHD and either total cholesterol or LDL cholesterol. '3' 14 Highly trained athletes have lower levels of cholesterol and LDL cholesterol, and higher levels of HDL cholesterol than do sedentary persons of the same age and sex; this is true of runners,'8 21 skiers,21 22 
